Last edition
News about
Verona Pharma Secures US FDA Approval of Ohtuvayre
Verona Pharma has announced that the US Food and Drug Administration (FDA) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Cipla and Takeda to Commercialize Vonoprazan in India
Cipla has signed a non-exclusive Patent License agreement with Takeda Pharmaceutical company Ltd. for ‘Vonoprazan’ for India Market for treating acid-related illnesses among patients.
Merck Announces Update on Xevinapant Program in Locally Advanced Head and Neck Cancer
Merck has discontinued the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy (CRT) in patients with unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
Sanofi and Biovac to Manufacture Inactivated Polio Vaccines in Africa
Sanofi has signed local manufacturing partnership with Biovacto to produce inactivated polio vaccines (IPV) in Africa.
Skyhawk Therapeutics Inaugurates its State-of-the-Art Labs in Switzerland
Skyhawk Therapeutics, Inc. has expanded its facilities with its new state-of-the-art labs in Superlab Suisse, in Basel Switzerland.
PrimeRx Launches PrimeRx Technology Solution
PrimeRx has introduced PrimeRx Cloud technology solution, a browser-based platform designed specifically for the needs of independent pharmacies.
Lilly and OpenAI to Revolutionize Medicines to Treat Drug-Resistant Bacteria
Eli Lilly and Company has signed a collaboration deal with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.
SkyCell Receives USD 116 Million in Series D Funding Round
SkyCell has recently secured a USD 116 million in Series D funding round.
Sen-Jam Pharma Completes Enrollment for Phase 2 URIs or COVID
Sen-Jam Pharmaceutical has completed participant enrollment for the clinical trial of its innovative therapeutic, SJP-002C in partnership with Duke University.
Cypris Therapeutics Bags Over USD 500k in Pre-Seed Funding
Cypris Therapeutics has introduced a breakthrough in synthetic chemistry technology which allows development of novel chemistries for treatment of therapeutically resistant diseases, including brain and pancreatic cancers.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy